More than 35 industry players claim to offer services for the identification, characterization and development<RootsAnalysis>
Drug discovery is challenging and involvesseveral complexities. In order to continue to add new molecules theirpipelines, drug developers are opting to outsource such operations to contractresearch organizations (CROs). Outsourcing of peptides and macrocycle drugdiscovery has emerged as one of the recent trends in the overall pharmaceuticaldomain.
To order this 180+page report, which features 90+ figures and 85+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/peptides-and-macrocycle-discovery/300.html
The USD 1.5 billion(by 2030) financial opportunity within the peptides and macrocycles drug discoveryservice and platform providers market has been analyzed across the followingsegments:
§ Type of peptides
§ Synthetic peptides
§ Biologic andrecombinant peptides
§ Type of discoverysteps
§ Target identificationand validation
§ Hit identification
§ Lead generation
§ Lead optimization
§ Therapeutic Area
§ Oncological disorders
§ Metabolic disorders
§ Cardiovasculardisorders
§ Infectious diseases
§ Urological disorders
§ Endocrine disorders
§ CNS disorders
§ Other diseases
§ Company Size
§ Small companies
§ Mid-sized companies
§ Large and very largecompanies
§ Key geographicalregions
- Europe
- North America
- Asia-Pacific and the Rest of the World
Thereport features inputs from eminent industry stakeholders, according to whompeptide and macrocycles drug discovery outsourcing market is continuouslypacing up. The report includes detailed transcripts of discussions held withthe following experts:
§ Mark I Peterson (CEO,CycleniumPharma)
§ Jan Hoflack (Chief Scientific Officer, Head ofBiotech Business Unit, Oncodesign)
Theresearch covers profiles of key players that offer peptides and macrocyclicdrugs discovery platforms and services, featuring an overview of the company,its service portfolio / technology platform, and an informed future outlook.
§ GenScript
§ JPT PeptideTechnologies
§ CPC Scientific
§ IRBM
§ Creative Peptides
§ Pepscan
§ Interprotein
§ RA Pharmaceuticals
§ Pepticom
§ PeptiDream
§ Creative Biolabs
§ MeSCue-Janusys
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Market Landscape of Service Providers
5. Benchmark Analysis
6. Market Landscape of Platform Providers
7. Company Profiles
8. Partnerships
9. Market Forecast and OpportunityAnalysis
10. SWOT Analysis
11. Conclusion
12. Executive Insights
13. Appendix 1: List of Companies andOrganizations
14. Appendix 1: Tabulated Data
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
